CHSPSC, LLC Antimicrobial Stewardship Education Series

Size: px
Start display at page:

Download "CHSPSC, LLC Antimicrobial Stewardship Education Series"

Transcription

1 CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine University of Illinois at Chicago Online Evaluation, Self-Assessment and CE Credit Submission of an online post test and evaluation is the only way to obtain CE credit for this webinar Go to Webinar attendees will also receive an with a direct link to the web page Print your CE statement of completion online Credit for live or enduring (not both) Deadline: April 7, 2017 CPE Monitor (applicable to pharmacists) CE credit automatically uploaded to NABP/CPE Monitor upon completion of post test and evaluation (user must complete the claim credit step) Attendance Code Code will be provided at the end of today s activity 2 1

2 How to Ask a Question Locate menu bar on your computer desktop Click orange arrow button Menu box will open Type question into question box Click Send Do not close menu box This will disconnect you from the Webcast Please submit questions throughout presentation Enter question Click No! Click Accessing PDF Handout No! Click the hyperlink that is located directly above the question box Do not close menu box This will disconnect you from the Webcast Click hyperlink 2

3 March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part Pharmacy Education Series Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine University of Illinois at Chicago It is the policy of to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Dr. Danziger has disclosed the following financial/commercial relationships: Speaker for Allergan, MedCo, and Merck. Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature. 5 CE Activity Information & Accreditation (Pharmacist CE) 1.0 contact hour Funding: This activity is self funded through CHSPSC

4 Antimicrobial Pharmacokinetics / Pharmacodynamics: Optimizing Therapeutic Outcomes March 8, 2017 Larry H. Danziger, Pharm.D Professor of Pharmacy and Medicine University of Illinois at Chicago 7 Objectives Upon completion of this presentation, the participant should be able to: Describe the pharmacodynamic (PD) properties of antimicrobials Identify strategies to maximize the PD properties in selecting and dosing antimicrobials Describe the factors to consider to safely prescribe Gentamicin and Vancomycin, to be able to monitor levels logically and interpret them 8 4

5 DeSear: Previous Discussion Selecting an antimicrobial agent and dosing scheme is based on a complex set of considerations What is the best pharmacodynamic (PD) predictor of efficacy for the drug chosen? AUC/MIC T>MIC C max : MIC How does the MIC impact PD? 9 Background The rational use of antibacterial drugs should be based upon two principles First, the specific identity of the infecting organism must be determined Second, a test must be devised which will provide an accurate estimate that the antibiotic will be effective in vivo Petersdorf and Plorde Annu. Rev. Med. 14:41-56;

6 Background Science has made tremendous progress over the last 30 years: Established critical values for outcome parameters that predict clinical & microbiologic success Identified PK parameters linked to a biologic measure of action, the MIC Devised tests to determine antibiotic performance characterized as concentration dependent or independent Established pharmacodynamic outcome parameters 11 Background Minimum inhibitory concentration (MIC) The lowest concentration of drug that prevents visible bacterial growth after 24 hours of incubation in a specified growth medium Organism and antimicrobial specific Interpretation Pharmacokinetics/Pharmacodynamics of the drug in humans Drug s activity versus the organism Site of infection Drug resistance mechanisms

7 Factors Influencing Clinical Outcome HOST BUG DRUG 13 Factors Influencing Clinical Outcome Site of infection Infecting pathogen Resistance of infecting pathogen Host - Protein binding Host - Immune system Drug class Dosing regimen (dose & duration) Treatment endpoint

8 Bug: How Do We Predict Antimicrobial Effect? Parameter Definition Limitations MIC (Minimum inhibitory concentration) MBC (Minimum bactericidal concentration) Concentration at which a standard inoculum of 10 5 organisms are inhibited after hours Concentration at which a 99.9% reduction in the standard inoculum occurs In vitro conditions differ from those at infection site Only reflects a specific time point In vitro drug concentrations remain constant Measured against standard inoculum Lacks information on: - Rate of bactericidal activity - Persistent effects In vitro tests may not adequately predict outcome Levison ME. Infect Dis Clin North Am 2000;14: Craig WA. Clin Infect Dis 1998;26: Host and Drug Factors Site of Infection Site defines the most likely organisms Especially helpful in empiric antimicrobial selection Site also determines the dose and route of administration of antimicrobial Efficacy determined by adequate concentrations of antimicrobial at site of infection Serum concentrations vs tissue concentrations and relationship to MIC

9 Optimizing Antimicrobial Therapy DRUG Pharmacokinetics Infection Site Pathogen MIC Host Bacteria Killed Pharmacodynamic Profile 17 Basic Pharmacokinetic Model Drug at Absorption Site Drug in Body Excreted Drug Metabolite in Body Eliminated Metabolite

10 Basic Pharmacodynamics Model Dosage regimen Concentration vs. time in serum Absorption Distribution Elimination Concentration vs. time in tissue and other body fluids Concentration vs. time at site of infection Pharmacologic or toxic effect Antimicrobial effect versus time Pharmacokinetics Pharmacodynamics Craig WA. Clin Infect Dis 1998;26: Pharmacokinetic Definitions C Max = Peak Concentration AUC C Min = Trough Time

11 PK / PD Definitions AUC = area under the serum concentration curve, measurement of drug absorbed and persistence AUC 24 /MIC ratio = AUC over 24 hours divided by the MIC, predicts efficacy of concentration-dependent antibiotics C max = peak plasma level, highest concentration of drug in the blood C max /MIC ratio = Peak/MIC ratio, predicts efficacy of concentration-dependent antibiotics 21 PK / PD Definitions C min = trough level T>MIC = time above MIC, percentage of time over 24 hours that drug concentration exceeds the MIC PAE = Post Antibiotic Effect, delayed regrowth of bacteria following exposure to an antibiotic Varies according to drug-bug combination

12 Efficacy and PK /PD Relationships Pharmacokinetics (PK) serum concentration profile penetration to site of infection Pharmacodynamics (PD) susceptibility MIC (potency) concentration- vs. time-dependent killing persistent (post-antibiotic) effects (PAE) Jacobs. Clin Microbiol Infect 2001;7: Antimicrobial Pharmacodynamics Correlates the drug concentration and the clinical effect (ie, bacteria killed) Often use surrogate marker such as minimum inhibitory concentration (MIC) Index serum concentration (pharmacokinetic profile) to MIC The pharmacodynamic relationship is different for different antimicrobial classes

13 PK / PD Relationships Microbiology Susceptibility Testing MIC Bactericidal Rate Pharmacokinetics Peak/Trough concentration AUC Half-life Pharmacodynamics AUC / MIC Peak / MIC Time > MIC 25 Important PD Parameters Concentration dependent C max /MIC: Optimize dose to produce higher unbound drug concentrations AUC/MIC: Optimize the dose and exposure to unbound drug concentrations Concentration Dependent agents bacterial killing as the drug concentrations exceed the MIC Peak/MIC (AUC/MIC) ratio important Quinolones, aminoglycosides Craig WA. Clin Infect Dis 2001;33(Suppl 3):S

14 Concentration Dependent Concentration C max = peak C max / MIC AUC/ MIC Aminoglycosides Fluoroquinolones Metronidazole Daptomycin Glycopeptides MIC C min = trough Adapted from: Roberts JA, et al. Crit Care Med.2009;37: Time 27 Log 10 CFU/ ml Conc.-Dependent Tobramycin Bacterial Killing Time-Kill Curves of P. aeruginosa Time (hours) Time-Dependent Control ¼ MIC 1 MIC 4 MIC 16 MIC 64 MIC Ticarcillin Craig WA, et al. Scand J Infect Dis, 1991;Suppl (74)

15 AUC/MIC and Survival Relationship for Quinolones Relationship between AUC/MIC ratio for the nonprotein bound fraction of levofloxacin and ciprofloxacin Scaglione F, et al. Antimicrob Agents Chemother Sep;47(9): Important PD Parameters Concentration independent T > MIC: Optimize duration of unbound drug concentration at or above the MIC Concentration Independent (Time-Dependent) agents kill bacteria when the drug concentrations exceed the MIC Time>MIC important Penicillins, cephalosporins, vancomycin Craig WA. Clin Infect Dis 2001;33(Suppl 3):S

16 Concentration Independent Concentration C max = peak Beta-lactams Clindamycin Macrolides Linezolid Vancomycin T > MIC MIC C min = trough Adapted from: Roberts JA, et al. Crit Care Med.2009;37: Time 31 Relationship between Time above MIC and efficacy in animal infection models Cefotaxime in K. pneumoniae Log 10 CFU per lung at 24 h Peak MIC ratio 24 h AUC/MIC ratio R² = 94% Time above MIC (%) Craig. Diagn Microbiol Infect Dis 1996; 25:

17 Relationship between Time above MIC and efficacy in animal infection models S. pneumoniae Penicillins Cephalosporins Time above MIC (%) Craig. Diagn Microbiol Infect Dis 1996; 25: PD of Specific Antimicrobials PD Parameter C max /MIC AUC/MIC T > MIC Aminoglycosides Fluoroquinolones Metronidazole Aminoglycosides Azithromycin Daptomycin Glycopeptides Ketolides Quinupristin/dalfopristin Beta-lactams Aztreonam Erythromycin Clarithromycin Linezolid Clindamycin Vancomycin Rodvold KA. Pharmacotherapy 2001;21:319S-330S. Nicolau DP. J Infect Chemother 2003;9:

18 Pharmacodynamic Parameters for Prediction of Successful Outcomes Concentration (mg/l) Peak/MIC 10x ( Gm - ) Aminoglycosides / Fluoroquinolones AUC/MIC >125 ( Gm - ) or >30 ( Gm + ) Fluoroquinolones AUC/MIC >100 Daptomycin or >50 Colistin Time > MIC >50% Cephalosporins / Macrolides Time (h) MIC 35 Post Antibiotic Effect (PAE) C max = peak Concentration Persistent suppression of bacterial regrowth following brief exposure to an antimicrobial PAE MIC C min = trough Time Adapted from: Roberts JA, et al. Crit Care Med.2009;37:

19 Post Antibiotic Effect (PAE) Gram-positive organisms Most antibiotics (beta-lactams) exhibit PAE ~1-2 hours Aminoglycosides exhibit PAE < 1 hour Prolonged for Fluoroquinolones Gram-negative organisms Most beta-lactams (except imipenem) have a negligible PAE Aminoglycosides and quinolones have PAE > 2-3 hours Prolonged for Fluoroquinolones Clinical significance unknown Helps choose appropriate dosing interval Craig w, et al. The Post Antibiotic Effect. Ann Inter Med1987;106(6): Clinical Applications Using PK and PD to predict patient outcome

20 Clinical response (%) Relationship Between C max :MIC Ratio and Clinical Response Aminoglycosides Moore RD et al. J Infect Dis. 1987;155: C max :MIC Relationship Between AUC / MIC and Clinical Response Ciprofloxacin in Seriously Ill Patients 100% - Clinical Microbiologic % of Patients Cured 75% - 50% % > 500 Forrest A., et al. Antimicrob Agents Chemother 1993;37:

21 No. of patients Relationship Between AUC / MIC and Clinical Response AUC:MIC <25 Peak:MIC <3 Success Failure Levofloxacin Clinical Failure Rate 43% 11.5% 1% 23 3 AUC:MIC Peak:MIC AUC:MIC >100 Peak:MIC > hospitalized patients with respiratory tract, skin or complicated urinary tract infections treated with 500 mg qd for 5 14 days Jacobs. Clin Microbiol Infect 2001;7: ; [Adapted from Preston et al. JAMA 1998;279:125 9] 41 Limitation of Pharmacodynamics Bacterial sample should be in the fluid where the bacteria is obtained: difficult if not impossible to obtain Technology for measuring MIC s has 100% variability (1-2 fold dilutions) Antibiotic PD parameters, f-auc/mic & f-peak/mic incorporate MIC in the denominator One tube dilution can double or half the value of your PD outcome predictor or change the amount of time where f-antibiotic concentration > MIC

22 Limitation of Pharmacodynamics All methods of determining MIC are not equal PD outcome parameter should specify MIC method Remember: Bacteria differ in their susceptibility to antibiotics, even among same species 43 Limitations of Pharmacokinetics Young healthy volunteers: worst case Most PK studies done in males Actual patients: clinically appropriate, usually not available May or may not account for protein-binding

23 Other Considerations 45 Will the antibiotic get to the site of Infection? Blood and tissue concentrations Ampicillin/piperacillin concentrations in bile Fluoroquinolones concentrations in bone Quinolones, TMP/SMX, cephalosporins, amoxicillin concentrations in prostate

24 Will the antibiotic get to the site of Infection? Ability to cross blood-brain barrier Dependent on inflammation, lipophilicity, low mw, low protein binding, low degree of ionization 3 rd or 4 th generation cephalosporins, chloramphenicol, ampicillin, PCN, oxacillin 47 Other Problems Local infection problems Aminoglycosides inactivated by low ph and low oxygen tension Beta-lactams inoculum effect More vulnerable to hydrolysis of betalactamases

25 Timing of Antibiotics 49 Early treatment of infection Compliance with the 6-hour sepsis bundle and hospital mortality (n = 101). NNT, number needed to treat; RR, relative risk Gao F, et al. Critical Care. 2005; 9:R

26 Requirements For Short Course Antibiotic Therapy Fully susceptible pathogen; no risk of selection of resistance Bactericidal antibiotics (or combination) with optimum dose/dosing regimen Rapid onset of antibiotic action Good penetration of antibiotic into the infection site Antibiotic active against non-dividing bacteria Antibiotic action not affected by adverse infection conditions No foreign body present No abscess formation No signs of immunodeficiency 51 Short Course Antimicrobial Therapy Disease Longer Treatment (days) Equally Effective Shorter Treatment (days) Abdominal infection 10 4 Bronchitis in people with Chronic Obstructive Pulmonary Disease (COPD) 7 or more 5 or fewer Bacterial sinus infection 10 5 Cellulitis (skin infection) 10 5 to 6 Chronic bone infection Kidney infection 10 to 14 5 to 7 Pneumonia acquired in the hospital Pneumonia acquired outside the hospital 10 to 15 8 or fewer 10 to 14 3 to 5 Adapted from: Spellberg B, The New Antibiotic Mantra: "Shorter is Better," JAMA Internal Medicine, July 25,

27 What Factors Promote Antimicrobial Resistance? Exposure to sub-optimal levels of antimicrobial Exposure to microbes carrying resistance genes 53 Traditional hypothesis on emergence of AMR Plasma concentrations MIC Selective pressure for antibiotic concentration lower than the MIC Time

28 The selection window hypothesis Plasma concentrations Mutant Selection window Mutant prevention concentration (MPC) (to inhibit growth of the least susceptible, single step mutant) MIC Selective concentration (SC) to block wild-type bacteria All bacteria inhibited Growth of only the most resistant subpopulation Growth of all bacteria Adapted from: Canton R, et al. Enferm Infecc Microbiol Clin 2013;31 Supl 4: Summary Antimicrobial PK/PD Through the integration of microbiologic data, pharmacodynamics data and pharmacokinetic parameters, determination of optimal antimicrobial therapy is possible DRUG BUG HOST

29

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,

More information

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* 44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine

More information

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections ...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

Jerome J Schentag, Pharm D

Jerome J Schentag, Pharm D Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday

More information

Principles of Antimicrobial therapy

Principles of Antimicrobial therapy Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or

More information

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1 Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases Case #2 68 y.o. female with HTN, anxiety with chest pain symptoms 7/27/05: Cath - 3 vessel

More information

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1 Introduction to Antimicrobial Therapy Objectives Review the classification of antimicrobials Define pharmacokinetic and pharmacodynamic principles and their relationship to effective antimicrobial therapy

More information

Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient

Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg

More information

Animal models and PK/PD. Examples with selected antibiotics

Animal models and PK/PD. Examples with selected antibiotics Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh

More information

Sustaining an Antimicrobial Stewardship

Sustaining an Antimicrobial Stewardship Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases

More information

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23

More information

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Case #1 Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases L.G. is a 78 yo woman admitted for cardiac cath. 3-vessel disease was identified and

More information

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

Does the Dose Matter?

Does the Dose Matter? SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC

More information

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for

More information

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Tom Dilworth, PharmD Aurora Health Care thomas.dilworth@aurora.org Objectives Describe the pharmacokinetics and pharmacodynamics

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

PK/PD to fight resistance

PK/PD to fight resistance PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International

More information

Antimicrobial therapy in critical care

Antimicrobial therapy in critical care Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting

More information

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University

More information

Percent Time Above MIC ( T MIC)

Percent Time Above MIC ( T MIC) 8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3

More information

P< cells/µl mg/dl P<0.01 P<0.01

P< cells/µl mg/dl P<0.01 P<0.01 Technical Reports Judicious Use of s for Pediatric Infection Global Strategies to Prevent the Increase of Bacterial Resistance Kazunobu OUCHI Principle of antimicrobial therapy in children is to select

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015 Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Curricular Components for Infectious Diseases EPA

Curricular Components for Infectious Diseases EPA Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin Classification of Antimicrobials Antimicrobials are drugs that destroy microbes, prevent their multiplication or growth, or prevent their pathogenic

More information

Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections

Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,

More information

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram

More information

Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development 136 Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development Mohd H. Abdul-Aziz, BPharm 1 Jeffrey Lipman, MD 1,2 Johan W.

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

General Infectious Disease Concepts/Resources

General Infectious Disease Concepts/Resources General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal

More information

Chapter 51. Clinical Use of Antimicrobial Agents

Chapter 51. Clinical Use of Antimicrobial Agents Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality

More information

Sepsis is the most common cause of death in

Sepsis is the most common cause of death in ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic

More information

Choosing an Antibiotic

Choosing an Antibiotic Principles of Antibiotic Use - The 6 Step Plan Robin J Green MBBCh, DCH, FC Paed, DTM&H, MMed, FCCP, PhD, Dip Allergy, FAAAAI Department of Paediatrics and Child Health 1 Choosing an Antibiotic Disease/Site

More information

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Arthur RH van Zanten, MD PhD Internist-intensivist Department of Intensive care Gelderse Vallei Hospital, Ede The Netherlands

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

LUNCH AND LEARN. January 13, CE Activity Information & Accreditation

LUNCH AND LEARN. January 13, CE Activity Information & Accreditation LUNCH AND LEARN Overview of Antimicrobial Stewardship January 13, 2017 Featured Speaker: Jamie Kisgen, PharmD, BCPS (AQ ID) Pharmacotherapy Specialist Infectious Diseases Antimicrobial Stewardship Program

More information

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs? Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

parameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an

parameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important

More information

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016 Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that

More information

Dr. NAFRIALDI, PhD, SpPD, SpFK

Dr. NAFRIALDI, PhD, SpPD, SpFK Dr. NAFRIALDI, PhD, SpPD, SpFK Lahir: Bukittinggi, 30 Oktober 1961. Pendidikan Dokter Umum: FKUI, 1986 S2 Farmakologi: Universite Claude Bernard, Lyon, Perancis, 1991 S3 Farmakologi: Universite Montpellier,

More information

Antimicrobial Stewardship in Ambulatory Care

Antimicrobial Stewardship in Ambulatory Care Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative

More information

Why we perform susceptibility testing

Why we perform susceptibility testing 22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform

More information

Journal of Antimicrobial Chemotherapy Advance Access published August 26, 2006

Journal of Antimicrobial Chemotherapy Advance Access published August 26, 2006 Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,

More information

ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC

ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC PREFACE INTRODUCTION The wide use and frequent misuse of antimicrobials in all countries has resulted in the emergence of drug resistance,

More information

Antibiotic stewardship in long term care

Antibiotic stewardship in long term care Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts

More information

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

More information

Systemic Antimicrobial Prophylaxis Issues

Systemic Antimicrobial Prophylaxis Issues Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.

More information

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections ...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1

More information

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different

More information

Postgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics

Postgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics Antibiotics and the lung: pharmacokinetics Educational aims To explain the importance of pulmonary deposition of antimicrobials. To show that drugs that penetrate well and remain at the pulmonary sites

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What

More information

American Association of Feline Practitioners American Animal Hospital Association

American Association of Feline Practitioners American Animal Hospital Association American Association of Feline Practitioners American Animal Hospital Association Basic Guidelines of Judicious Therapeutic Use of Antimicrobials August 1, 2006 Introduction The Basic Guidelines to Judicious

More information

TDM of antibiotics. Paul M. Tulkens, MD, PhD

TDM of antibiotics. Paul M. Tulkens, MD, PhD TDM of antibiotics (Laboratory testing guideline in the intensive care unit) Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain,

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Rational use of antibiotics

Rational use of antibiotics Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis

More information

MANAGING ANTIBIOTIC THERAPY

MANAGING ANTIBIOTIC THERAPY MANAGING ANTIBIOTIC THERAPY ITS MORE THAN JUST ABOUT THE S AND THE R Larry M. Bush, MD, FACP Affiliated Professor of Biomedical Science Charles E. Schmidt College of Medicine Florida Atlantic University

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review (1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of

More information

Is erythromycin bactericidal

Is erythromycin bactericidal Is erythromycin bactericidal Search Comparison of erythromycin, clarithromycin, azithromycin, telithromycin, roxithromycin: mechanism of action, spectrum of activity, side effects, drug interactions. Erythromycin

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information